Sort
326,823 grants matching “clinical trial”
IMPACTA PERU CLINICAL TRIALS UNIT
$2,046,610Jorge Luis Sanchez · Asociacion Civil Impacta Salud Y Educacn · UM1 · FY2015 · AI
Investigation On The Behavior And Related Neuro-Electrochemistry Of Potential Medications For The Treatment Of Substance Use Disorders.
$2,046,473Gianluigi Tanda · National Institute On Drug Abuse · ZIA · FY2023 · DA
CENTER FOR PSYCHO-ONCOLOGY RESEARCH
$2,046,384University Of Miami Coral Gables · P50 · FY2000 · CA
Clinical sequencing in cancer: Clinical ethical and technological studies
$2,046,280Gail Pairitz Jarvik · University Of Washington · U01 · FY2014 · HG
Targeted antigen receptor treatment of cancer
$2,046,251Sloan-Kettering Institute For Cancer Res · P01 · FY2005 · CA
Emergency General Surgery Delirium Recovery Model: A Collaborative Care Intervention
$2,046,154Ben L Zarzaur · University Of Wisconsin-Madison · R01 · FY2024 · AG
Florida Node Alliance of the Drug Abuse Clinic Trials Network
$2,046,113Jose Szapocznik · University Of Miami School Of Medicine · U10 · FY2014 · DA
Treat-to-Target Serum Urate versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial (TRUST)
$2,046,055Hyon K Choi · Massachusetts General Hospital · U01 · FY2023 · AR
Elafin Therapy for Lung Diseases
$2,045,899Marlene Rabinovitch · Stanford University · P01 · FY2013 · HL
Novel, Non-hormonal Therapeutic for Endometriosis
$2,045,782Tanya Christineh Petrossian · Endomet Biosciences, Inc · SB1 · FY2025 · HD
Product Development and Manufacture
$2,045,526Robert T McNally · Geovax, Inc. · U19 · FY2010 · AI
Androgen Receptor Action in Castration Resistant Prostate Cancer
$2,045,478Steven P. Balk · Beth Israel Deaconess Medical Center · P01 · FY2017 · CA
Androgen Receptor Action in Castration Resistant Prostate Cancer
$2,045,071Steven P. Balk · Beth Israel Deaconess Medical Center · P01 · FY2016 · CA
Genetic Neurobiology Of Drosophila
$2,045,040Howard A Nash · National Institute Of Mental Health · Z01 · FY2008 · MH
SPORE for Translational Approaches to Brain Cancer
$2,044,971Maciej S Lesniak · Northwestern University At Chicago · P50 · FY2023 · CA
Iowa Phase II Clinical Trials of Novel Therapies for Lung Diseases (U01
$2,044,958Lakshmi Durairaj · University Of Iowa · U01 · FY2012 · HL
Ancillary Study 1
$2,044,958Joseph Zabner · University Of Iowa · U01 · FY2012 · HL
Harvard Reproductive Endocrine Sciences Center
$2,044,861William F Crowley · Massachusetts General Hospital · U54 · FY2012 · HD
Vaccine and Treatment Evaluation Units
$2,044,564Nadine Georges Rouphael · Emory University · UM1 · FY2021 · AI
Innate Immunity: Elucidation and Modulation for Cancer Therapy
$2,044,559Michael A Caligiuri · Ohio State University · P01 · FY2009 · CA
VICKtOrY Early Clinical Trials Consortium
$2,044,455Patricia M Lorusso · Yale University · UM1 · FY2023 · CA
P1115 - VERY EARLY INTENSIVE TREATMENT OF HIV-INFECTED INFANTS TO ACHIEVE HIV REMISSION: A PHASE I/II PROOF OF CONCEPT STUDY
$2,044,287Barbara Driver · Westat, Inc. · N01 · FY2024 · HD
Cincinnati Comprehensive Sickle Cell Center
$2,044,252Clinton H. Joiner · Cincinnati Childrens Hosp Med Ctr · U54 · FY2006 · HL
Biomarkers of Developmental Trajectories and Treatment in ASD
$2,044,233Susan Y Bookheimer · University Of California Los Angeles · P50 · FY2016 · HD
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
$2,044,217Fred R Hirsch · Icahn School Of Medicine At Mount Sinai · U54 · FY2022 · CA